Transgene, Virax deal

Transgene received U.S. and Canadian rights to use VHL's Co-X-Gene immunotherapy technology for Transgene's TG4010 and TG4001 therapeutic DNA vaccines. TG4010, which expresses MUC-1 ( CD227) and in...